Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2011 1
2012 1
2013 2
2014 1
2015 1
2016 1
2018 2
2019 2
2020 2
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Mahlangu J, et al. Among authors: adamkewicz ji. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. N Engl J Med. 2018. PMID: 30157389 Free article. Clinical Trial.
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K, Schmitt C, Portron A, Kiialainen A, Kotani N, Jaminion F, Retout S, Adamkewicz JI. Yoneyama K, et al. Among authors: adamkewicz ji. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):775-790. doi: 10.1080/17512433.2023.2243213. Epub 2023 Aug 21. Expert Rev Clin Pharmacol. 2023. PMID: 37529848 Review.
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.
Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, Smith V, Adamkewicz JI, Christiansen C, Leeming DJ. Karsdal MA, et al. Among authors: adamkewicz ji. Assay Drug Dev Technol. 2013 Mar;11(2):70-92. doi: 10.1089/adt.2012.474. Epub 2012 Oct 9. Assay Drug Dev Technol. 2013. PMID: 23046407 Free PMC article. Review.
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.
Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Yang J, et al. Among authors: adamkewicz j. Nat Commun. 2016 Dec 14;7:13710. doi: 10.1038/ncomms13710. Nat Commun. 2016. PMID: 27966531 Free PMC article.
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P. Pollheimer MJ, et al. Among authors: adamkewicz j. J Hepatol. 2018 Aug;69(2):368-377. doi: 10.1016/j.jhep.2018.04.009. Epub 2018 Apr 28. J Hepatol. 2018. PMID: 29709678
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Chien JW, et al. Among authors: adamkewicz ji. Eur Respir J. 2014 May;43(5):1430-8. doi: 10.1183/09031936.00141013. Epub 2013 Oct 31. Eur Respir J. 2014. PMID: 24177001 Free article. Clinical Trial.
16 results